P/B
15,3
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
$65.8M
Market Cap • 10/14/2026
2013
(13 years)
Founded
2018
(8 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
2,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,3
EPS
—
Market Cap
Market Cap
65,8M
EV
56,4M
EV/Revenue
1,9
EV/EBITDA
-2
EV/EBIT
-2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-347,7M
Profitability
Gross Margin
85,9%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
48,2%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
5,6%
% Goodwill
0%
ROE
473,3%
ROIC
—
Growth
CAGR Revenue 5Y
20,4%
CAGR Op. Income 5Y
-2,6%
CAGR Net Income 5Y
-2,9%
CAGR EPS 5Y
-34,7%
CAGR OCF 5Y
-9,5%
Leverage
N.D./EBITDA
0,3
Debt/Equity
0%
Current Ratio
1,5
Quick Ratio
1,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!